Collaborations, Global Platforms, and Strong Sales Drive Revenue Growth - Research Report on Baxter, Mylan, ImmunoGen, Emeritus, and Synta

NEW YORK, August 7, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Baxter International Inc. (NYSE: BAX), Mylan Inc. (NASDAQ: MYL), ImmunoGen, Inc. (NASDAQ: IMGN), Emeritus Corporation (NYSE: ESC), and Synta Pharmaceuticals Corp. (NASDAQ: SNTA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Baxter International Inc. Research Report

On July 31, 2013, Baxter International Inc. (Baxter) announced that it has entered into an exclusive distribution and license agreement with JW Holdings (JW Holdings) for production and distribution of parenteral nutritional products containing a novel formulation of omega 3 lipids. Baxter stated that under the terms of the agreement, the Company will have exclusive rights to co-develop and distribute the products globally, other than Korea. The arrangement also includes a $25 million upfront payment that will be recorded as a special pre-tax in-process research and development charge in Q3 2013. Further, Baxter stated that the agreement calls for payments totaling up to $10 million for the achievement of regulatory milestones, along with royalties on future product sales. The agreement will be in effect for 10 years following the first product launch, outside of Korea. The Companies have agreed to share the development costs and global clinical trials and registrations, equally. The Full Research Report on Baxter International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/163d_BAX]

--

Mylan Inc. Research Report

On August 1, 2013, Mylan Inc. (Mylan) reported its financial results for Q2 2013. The Company's total revenues increased 0.8% YoY to $1.7 billion, and net earnings attributable to Mylan shareholders were up 28.2% YoY to $177.7 million, or $0.46 per diluted share. Commenting on the results, John Sheehan, Mylan's Chief Financial Officer, said, "We saw continued robust growth in Europe, marking the fourth consecutive quarter of growth in this region, as well as solid double-digit growth in Asia Pacific. We also continued to see double-digit growth in our Specialty business and now expect this segment to deliver growth of closer to 20% for the year, with out-performance in other areas of our business off-setting this slower trajectory." Mylan's Chief Executive Officer, Heather Bresch, added, "We continue to anticipate strong performance across our global platform for the remainder of the year and are reaffirming our 2013 adjusted diluted EPS guidance range of $2.75 - $2.95 per share." The Full Research Report on Mylan Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/5a20_MYL]

--

ImmunoGen, Inc. Research Report

On August 2, 2013, ImmunoGen, Inc. (ImmunoGen) reported its financial results for Q4 FY 2013 (period ended June 30, 2013). The Company's total revenues grew 29.8% YoY to $3.8 million during the quarter. Net loss was $21.9 million, or $0.26 per diluted share, in Q4 FY 2013, compared to a net loss of $22.4 million, or $0.29 per diluted share, in Q4 FY 2012. Daniel Junius, President and CEO of ImmunoGen, said, "Kadcyla sales are off to a strong start in the US for its first indication, with many additional approvals expected. It is particularly gratifying to hear from patients about the difference Kadcyla is making for them and their caregivers." The Full Research Report on ImmunoGen, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/11c8_IMGN]

--

Emeritus Corporation Research Report

On August 1, 2013, Emeritus Corporation (Emeritus) reported its financial results for Q2 2013. The Company's total operating revenues were up 27.0% YoY to $475.9 million during the quarter. Net loss attributable to Emeritus common shareholders was $36.0 million, or $0.77 per diluted share, in Q2 2013, compared to a net loss of $21.7 million, or $0.49 per diluted share, in Q2 2012. Commenting on the results, Granger Cobb, President and CEO of Emeritus, said, "We were very pleased to see occupancy rebound with a 20-basis point sequential lift in our same store portfolio after the effects of a rough flu season in the first quarter. The continued integration of home healthcare services into our communities through our Nurse On Call subsidiary is making solid progress, and we look forward to on-boarding 38 high quality communities and benefitting from their operating teams' experience later in the quarter." The Full Research Report on Emeritus Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/d611_ESC]

--

Synta Pharmaceuticals Corp. Research Report

On August 1, 2013, Synta Pharmaceuticals Corp. (Synta) reported its financial results for Q2 2013. The Company did not recognize revenues for Q2 2013 and Q2 2012. Research and development expenses were up 58.9% YoY to $17.9 million in Q2 2013. Net loss was $22.8 million, or $0.33 per diluted share, in Q2 2013, compared to net loss of $14.6 million, or $0.25 per diluted share, in Q2 2012. Safi Bahcall, President and CEO of Synta said, "We are encouraged both by the promising clinical results and the growing medical community interest in working with ganetespib. We look forward to completing our GALAXY-2 Phase 3 trial in lung cancer, entering the next stage of development in breast cancer, and bringing ganetespib to patients as quickly as possible." The Full Research Report on Synta Pharmaceuticals Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/8ecc_SNTA]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Analysts' Corner